Summary
Quest Diagnostics Incorporated (DGX) has reported the completion of its acquisition of American Medical Laboratories, Incorporated (AML) for approximately $500 million in an all-cash transaction, which includes the assumption and retirement of approximately $160 million in debt. This strategic acquisition was financed through borrowings under existing credit facilities and existing cash reserves, signaling a significant expansion for Quest Diagnostics. The filing also details the integration of AML's subsidiaries and related entities, as well as the formation of new limited liability companies and their subsequent guarantees of Quest Diagnostics' outstanding debentures and notes.
Key Highlights
- 1Completion of the acquisition of American Medical Laboratories, Inc. (AML) for approximately $500 million in cash.
- 2The acquisition includes the assumption and retirement of approximately $160 million of AML's debt.
- 3Financing for the transaction was sourced from Quest Diagnostics' revolving credit facilities and cash on hand.
- 4New subsidiaries, referred to as 'Additional Subsidiary Guarantors,' have been established and will guarantee existing Quest Diagnostics debt instruments.
- 5These guarantees cover 1.75% Contingent Convertible Debentures due 2021, 6 3/4% Senior Notes due 2006, and 7 1/2% Senior Notes due 2011.
- 6The new entities also become subsidiary sellers under the company's existing Receivables Sale Agreement.
Frequently Asked Questions
This 8-K filing announces the completion of Quest Diagnostics' acquisition of American Medical Laboratories, Inc. (AML) and details the financial and legal steps taken in connection with this acquisition, including debt assumption and the guarantor status of new subsidiaries.
The acquisition was financed through a combination of borrowings under Quest Diagnostics' existing revolving credit facilities and approximately $30 million in cash on hand. The transaction was an all-cash deal valued at roughly $500 million.
The formation of new limited liability companies (LLCs) and the consolidation of AML's subsidiaries into 'Additional Subsidiary Guarantors' is important because these entities are now guaranteeing Quest Diagnostics' existing public debt. This action reinforces the creditworthiness of the issued debentures and notes by broadening the pool of guarantors.
The acquisition involved assuming and retiring $160 million of AML's debt, which simplifies the company's debt profile. Furthermore, the new subsidiaries becoming guarantors strengthens the security for Quest Diagnostics' outstanding 1.75% Contingent Convertible Debentures, 6 3/4% Senior Notes, and 7 1/2% Senior Notes.